Transport of the Ruthenium Complex [Ru(GA)(dppe)2]PF6into Triple-Negative Breast Cancer Cells Is Facilitated by Transferrin Receptors

Authors:

Abstract
The triple negative breast cancer subtype (TNBC) is highly aggressive, metastatic and corresponds to 15-20% of diagnosed cases. TNBC treatment is hampered because these cells usually do not respond to hormonal therapy and develop resistance to chemotherapeutic drugs. On the other hand, the severe side effects of cisplatin represent an obstacle for its clinical use. Ruthenium (Ru)-based complexes have emerged as promising antitumor and antimetastatic substitutes for cisplatin. In this study, we demonstrated the effects of a Ru/biphosphine complex, containing gallic acid (GA) as a ligand, [Ru(GA)(dppe)2]PF6, hereafter called Ru(GA), on a TNBC cell line, comparing to the effects in a non-tumor breast cell line. Ru(GA) complex presented selective citotoxicity against TNBC over non-tumor cells, inhibited its migration and invasion and induced apoptosis. These effects were associated with the increased amount of transferrin receptors (TfR) on tumor cells, compared to non-tumor ones. Silencing of TfR decreased Ru(GA) effects on TNBC cells, demonstrating that these receptors were at least partially responsible for Ru(GA) delivery into tumor cells. The Ru(GA) compound must be further studied in different in vivo assays in order to investigate its antitumor properties and its toxicity in complex biological systems.
Funding Information
  • Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico
  • Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo (2013/00798-2, 2015/24940-8, 2016/16312-0)
  • Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior (001)

This publication has 64 references indexed in Scilit: